China’s Innovative Drug Overseas Licensing Deals Continue to Heat Up: Cross-Border BD Transactions Hit a New High in the First Half of 2026

Since 2026, the activity of Chinese innovative drug companies participating in global pharmaceutical industry cooperation has continued to increase. Overseas license transactions, cross-border BD, and international commercialization cooperation are becoming important ways for Chinese biopharmaceutical companies to connect with the global market.

Industry data shows that in the first half of 2026, the number and value of overseas licensing deals involving Chinese companies for innovative drugs remained at a high level. Xinhua Silk Road, citing industry data, reported that the total value of overseas license transactions for Chinese innovative drugs reached a historical high in the first half of 2026, with Chinese companies participating in 8 of the top 10 global innovative drug license deals.

At the same time, China’s National Medical Products Administration recently stated that the country will further support drug innovation, strengthen the construction of the innovative drug R&D system, and support Chinese pharmaceutical companies in expanding into overseas markets.

These changes indicate that the international BD of Chinese healthcare companies is gradually developing from simple overseas market expansion to an important component of innovative asset licensing, cross-border R&D cooperation, and global commercialization layout.

I. China’s Innovative Drug Overseas Licensing Deals Remained Active in 2026

In recent years, Chinese innovative drug companies have continuously entered the international market through license-out arrangements.

According to a Xinhua Silk Road report in September 2026, the total value of overseas license transactions for Chinese innovative drugs reached a historical high in the first half of 2026, with Chinese companies participating in 8 of the top 10 global innovative drug license deals.

A review of industry transactions by BioPharma Dive in September 2026 also showed that license deals between Chinese biotech companies and American and European pharmaceutical companies remained active.

In terms of transaction models, Chinese companies are connecting their innovative drug assets with the R&D, registration, and commercialization capabilities of large global pharmaceutical companies through license-out deals.

This model allows innovative assets to gain new development and commercialization opportunities in different markets, while also enabling Chinese innovative drug companies to receive upfront payments, milestone payments, and future sales-related income.

II. Large-Value License Deals Become the Focus of Industry Attention

Some recent transactions further reflect the active level of international BD for Chinese innovative drug companies.

In September 2026, the British pharmaceutical company GSK announced an agreement with China’s Chimagen Biosciences to acquire the global rights to a T-cell engager (TCE) asset for multiple myeloma. Public reports show that the potential total value of the deal could reach up to $750 million, including an undisclosed upfront payment and subsequent payments related to R&D and commercialization progress. The project is expected to enter Phase I clinical trials in 2027.

This transaction is a typical innovative drug license-out model:

Chinese Innovative Asset + International Pharma’s R&D and Commercialization Capabilities + Phased Transaction Payments.

For innovative drug companies in the early or clinical development stage, this cooperation method allows them to share the value of the asset while leveraging the global resources of an international partner to advance product development.

III. The Headline Value of License Deals and Actual Cash Income Need to Be Differentiated

As the number of large-scale license deals increases, an important question for the market is:

Is the potential total value announced for a deal equal to the cash the company can receive at the time of signing?

The answer is usually no.

Healthcare license transactions are typically composed of multiple parts, including:

Upfront Payment
Development Milestones
Regulatory Milestones
Commercial Milestones
Royalties

Therefore, the “maximum potential transaction value” announced in a deal announcement usually includes milestone payments that may be triggered in the future and does not represent the full amount being paid at the time of signing.

Recent industry reports from Shanghai have also noted this difference. Relevant reports, citing industry data, stated that in the first eight months of 2026, Shanghai recorded a total of 37 biopharma BD deals with a disclosed potential transaction value of $18.23 billion; nationwide, Chinese companies signed 81 overseas license deals for innovative drugs in the first half of 2026, with a potential total value of about $110 billion. However, the disclosed upfront payment amounts were significantly lower than the potential total transaction values.

Therefore, when analyzing a license transaction, it is necessary to pay attention to:

Total transaction value, upfront payment, milestone conditions, royalty arrangements, and the development stage of the asset.

IV. Why Are China’s Innovative Drugs Increasingly Focusing on Overseas Licensing?

There are multiple industrial factors behind the increase in overseas licensing cooperation for Chinese innovative drug companies.

1. The Scale of China’s Innovative Drug R&D Continues to Expand

According to relevant information from the Chinese government, 76 innovative drugs were approved for marketing in China in 2025, a record high.

As of the end of 2025, there were 4,751 innovative drugs in the R&D pipeline in China, accounting for about one-third of the global innovative drug R&D pipeline, ranking first in the world.

As the number of innovative drug assets increases, companies need to find more ways to realize the commercial value of their R&D assets.

Overseas licensing has therefore become one of the important paths for asset value realization.

2. International Pharmaceutical Companies Need New Sources of Innovative Assets

Large global pharmaceutical companies continuously face the need to update their product pipelines and acquire innovative assets.

For large pharmaceutical companies with global R&D, registration, and commercialization systems, acquiring external innovative assets through license-in can be a way to supplement their internal R&D pipelines.

This has created a new industrial cooperation relationship between Chinese innovative drug companies and global pharmaceutical companies:

Chinese companies provide innovative assets, and international pharmaceutical companies provide global development and commercialization resources.

Of course, the specific value of the cooperation still depends on factors such as the product’s clinical data, intellectual property, competitive landscape, target market, and the partner’s capabilities.

V. From “Selling Assets” to “Global BD”

The increase in overseas license transactions also means that the internationalization methods of Chinese healthcare companies are changing.

In the past, when companies entered overseas markets, they often first considered:

Establishing an overseas sales team;
Establishing an overseas subsidiary;
Finding local distributors;
Conducting overseas registration themselves.

Now, more and more innovative drug companies are starting to enter overseas markets through different forms of international BD, including:

License-out;
License-in;
Co-development;
Co-commercialization;
Strategic Partnership;
Joint Venture.

Different models correspond to different capital investments, risk assumptions, and commercialization responsibilities.

Therefore, internationalization does not mean that a company must establish a complete commercialization system in every market.

Companies can also choose based on their own resources:

Self-operation in core markets + Licensing in non-core markets

Or:

Retaining the China market + Licensing out overseas regions

and other different strategies.

VI. Overseas License Transactions Still Need to Pay Attention to the Regulatory and Policy Environment

The development of cross-border healthcare transactions is also affected by the international regulatory and policy environment.

In September 2026, Reuters reported that the United States is developing rules related to investment in Chinese medicine, and the relevant plan may allow US pharmaceutical companies to continue to conduct most drug license transactions with Chinese companies, but may exclude transactions involving potentially weaponizable pathogens or related biotechnology. The report also pointed out that the relevant rules are still being formulated, and the final arrangements may change.

This policy dynamic illustrates that:

Cross-border license transactions are not only a commercial issue, but also need to consider the target market’s regulation, investment review, data compliance, and intellectual property environment.

For healthcare companies planning to conduct international BD, they need to fully assess the policy environment of the target market before determining partners and transaction structures.

VII. The Competitive Focus of International BD for Innovative Drugs is Changing

As the number of overseas transactions for Chinese innovative drugs increases, the competition between companies may no longer be just:

“Who has an innovative drug project?”

But gradually shift to:

“Who can prove that their asset has global development and commercialization value?”

Therefore, international BD increasingly needs to focus on the following aspects:

Clinical Value

Does the product address a clear clinical need?

Differentiation

Compared with existing products, does it have advantages in efficacy, safety, administration, or other aspects?

Intellectual Property

Can the scope of patent protection and the remaining protection period support long-term commercialization?

Global Development Path

Is the overseas clinical and registration path clear?

Commercialization Potential

Is there a sufficient patient population and commercialization space in the target market?

Partner Matching

Does the potential licensee have the R&D, registration, and commercialization capabilities required for the target region?

These factors together determine the international BD value of an innovative asset.

VIII. What Does This Mean for Chinese Healthcare Companies?

The current active state of overseas license transactions provides more international cooperation opportunities for Chinese healthcare companies.

However, for companies, international BD does not mean simply pursuing higher transaction amounts.

What a license transaction really needs to focus on is:

Which regions are licensed?
What rights are licensed?
How much is the upfront payment?
How are the milestones set?
How are the royalties arranged?
Who bears the subsequent R&D costs?
Who is responsible for registration?
Who is responsible for commercialization?
If the project does not advance for a long time, does the company have an exit or rights-reversion mechanism?

These questions ultimately determine the impact of the transaction on the company’s long-term value.

Therefore, the core of international BD is not simply to license out assets, but to obtain greater development and commercialization opportunities for innovative assets in the global market through reasonable transaction structures and partner selection.

Conclusion

Since 2026, overseas license transactions for Chinese innovative drugs have continued to attract attention from the global healthcare industry.

From Chinese companies participating in large-scale global innovative drug licensing deals to international pharmaceutical companies continuously acquiring assets from Chinese innovative drug companies, cross-border BD is becoming an important part of global pharmaceutical industry cooperation.

At the same time, Chinese regulatory authorities are also continuing to promote the R&D of innovative drugs and medical devices, and have proposed to support Chinese pharmaceutical companies in expanding into overseas markets.

For Chinese healthcare companies, future internationalization may no longer be limited to the single path of “going overseas on their own.”

License-out, license-in, co-development, strategic partnerships, and cross-border M&A can all become tools for connecting China’s innovation capabilities with the global healthcare market.

For corporate management, the focus of the next stage will not only be “whether to conduct international BD,” but:

What assets are suitable for internationalization, which markets should be chosen, what kind of partners to look for, and how to design a transaction structure that can balance short-term cash flow and long-term asset value.

China's Innovative Drug Overseas Licensing Deals Continue to Heat Up: Cross-Border BD Transactions Hit a New High in the First Half of 2026